Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension
StockNews.AI · 2 hours
AI Summary
Insmed announced positive 12-month data from TPIP’s open-label extension in PAH, showing sustained improvements in 6MWD, NT-proBNP, WHO Functional Class, and REVEAL Lite 2.0 risk scores, with placebo-crossed patients achieving similar outcomes. Safety remained acceptable up to 1,280 µg daily; PALM-PAH Phase 3 is underway, potentially accelerating TPIP’s approval pathway.
Sentiment Rationale
The data de-risks the TPIP program, reinforces clinical benefit signals, and supports a near-term Phase 3 pathway, which can lift valuation and attract investor attention ahead of PALM-PAH milestones.
Trading Thesis
Bullish over 6–12 months as TPIP data de-risks the PAH program and supports PALM-PAH progress.
Market-Moving
- Positive 12-month TPIP OLE data may trigger near-term upside for INSM.
- PALM-PAH Phase 3 readout catalysts could re-rate TPIP’s valuation.
- Dosing up to 1,280 µg daily strengthens the safety narrative.
- July 16, 2026 investor call could drive intraday momentum.
Key Facts
- 12-month OLE TPIP data shows sustained 6MWD and NT-proBNP gains.
- Placebo Crossed group matched TPIP outcomes at Month 12.
- Doses up to 1,280 µg daily tolerated.
- PALM-PAH Phase 3 underway; investor call July 16, 2026.
- TPIP may become PAH prostanoid of choice.
Companies Mentioned
- Insmed Incorporated (INSM): Release highlights 12-month TPIP OLE PAH data; potential PALM-PAH catalyst.
- PALM-PAH (N/A): Phase 3 trial of TPIP in PAH; potential data catalyst.
Industry News
Category: Industry News. The article updates Insmed’s TPIP program with pivotal 12-month OLE data, signaling potential near-term catalysts and shaping expectations for the Phase 3 PALM-PAH trial.